Daprodustat

Cat. No.: HY-17608
CAS No.: 960539-70-2
Molecular Formula: C₁₉H₂₇N₃O₆
Molecular Weight: 393.43
Target: HIF/HIF Prolyl-Hydroxylase
Pathway: Metabolic Enzyme/Protease
Storage:
- Powder: -20°C for 3 years, 4°C for 2 years
- In solvent: -80°C for 6 months, -20°C for 1 month

Solvent & Solubility

In Vitro: DMSO: 19.5 mg/mL (49.56 mM; Need ultrasonic and warming)

<table>
<thead>
<tr>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.5417 mL</td>
<td>12.7087 mL</td>
<td>25.4175 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.5083 mL</td>
<td>2.5417 mL</td>
<td>5.0835 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2542 mL</td>
<td>1.2709 mL</td>
<td>2.5417 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description: Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for the treatment of anemia associated with chronic kidney disease.

In Vitro: GSK1278863 is an orally administered small-molecule PHI, and stimulates endogenous EPO synthesis and induce effective erythropoiesis\(^1\). GSK1278863 has been shown to increase erythropoietin levels, leading to increases in hemoglobin, hematocrit and red blood cell numbers\(^2\).

REFERENCES


\(^2\) Hara K, et al. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy